Drug Trial Radar · NCT05645692
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
204
Actual
Start
Apr 13, 2023
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.
Conditions
- Urothelial Cancer
Interventions
AtezolizumabDrug
Participants will receive 1200 mg IV atezolizumab Q3W.
TobemstomigDrug
Participants will receive 600 mg IV tobemstomig Q3W.
TiragolumabDrug
Participants will receive 600 mg IV tiragolumab Q3W.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Adverse EventsTime frame: Up to approximately 30 months
Locations
56 sites in 15 countries. Site status is shown where the registry gives one.
Cleveland Clinic
Cleveland, Ohio
MD Anderson Cancer Center
Houston, Texas
Macquarie University Hospital
Macquarie Park, New South Wales, Australia
Lyell McEwin Hospital
Adelaide, South Australia, Australia
ICON Cancer Care Adelaide
Kurralta Park, South Australia, Australia
Hospital Universitario Evangelico De Curitiba
Curitiba, Paraná, Brazil
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Amor Amazônia
Porto Velho, Rondônia, Brazil
*X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
Santo André, São Paulo, Brazil
Hospital Alemao Oswaldo Cruz
São Paulo, São Paulo, Brazil
Beijing Cancer Hospital
Beijing, China
West China Hospital - Sichuan University
Chengdu, China
Sun yat-sen University Cancer Center
Guangzhou, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Aarhus Universitetshospital
Aarhus N, Denmark
Herlev Hospital
Herlev, Denmark
Centre Leon Berard
Lyon, France
Gustave Roussy
Villejuif, France
Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie
Halle, Germany
Martini-Klinik am UKE GmbH
Hamburg, Germany
Alexandras General Hospital of Athens
Athens, Greece
Attikon University General Hospital
Chaïdári, Greece
Theageneio Hospital
Thessaloniki, Greece
A.O. Universitaria Ospedale Consorziale Policlinico Di Bari
Bari, Apulia, Italy
Istituto Nazionale Tumori Irccs Fondazione G. Pascale
Naples, Campania, Italy
Azienda Ospedaliero-Universitaria S.Orsola-Malpighi
Bologna, Emilia-Romagna, Italy
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola
Meldola, Emilia-Romagna, Italy
Policlinico Universitario "Agostino Gemelli"
Rome, Lazio, Italy
Irccs Ospedale San Raffaele
Milan, Lombardy, Italy
Azienda Ospedaliera S. Maria - Terni
Terni, Umbria, Italy
IRCCS Istituto Oncologico Veneto (IOV)
Padova, Veneto, Italy
Health Pharma Professional Research
Mexico City, Mexico CITY (federal District), Mexico
Szpital Wojewódzki im. Miko?aja Kopernika
Koszalin, Poland
Szpital Uniwersytecki w Krakowie
Krakow, Poland
Pratia Poznan
Późna, Poland
Szpital Grochowski im. dr med. Rafa?a Masztaka Sp. z o.o.
Warsaw, Poland
Seoul National University Bundang Hospital
Gyeonggi-do, South Korea
Gachon University Gil Medical Center
Incheon, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University
Seoul, South Korea
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.